ST. LOUIS, Mo. - Age is one of the most significant risk factors for cancer and numerous Medicare beneficiaries face an unmet need for early cancer detection.
Mercy, the multi-state health system providing comprehensive care through hospitals, clinics, and virtual services across the Midwest, is stepping into a study to evaluate the clinical impact of GRAIL’s Galleri, a multi-cancer early detection test among Medicare beneficiaries.
Headquartered in Menlo Park, California, GRAIL’s 2025 Pathfinder 2 study found that of more than 23,000 people tested, the Galleri test found a cancer signal (positive) in 216 individuals, leading to 133 confirmed cancer diagnoses.
“We are always looking for innovative screening and treatment options, said Damon Broyles, Mercy’s vice president of clinical innovation, medical director for MCED and REACH study principal investigator. “So, it was important to us to participate in the REACH study to help expand upon the real-world evidence of the Galleri test, in order to build upon the evidence base that can help extend access to Medicare beneficiaries.”
“Across four states, a team of more than 2,400 Mercy primary and specialty care physicians, more than 2,200 advanced practitioners, and supporting staff deliver health care services through more than 300 offices,” Mercy’s website states.
The three-year REACH study will compare up to 50,000 Medicare beneficiaries who have received care in addition to an annual Galleri test to those who receive care without a Galleri test. Medicare recipients who are at least 50 years old may be eligible for the study. For more details, email MercyResearchREACHStudy@ mailto:Study@Mercy.Net Mercy.Net.